Clinical trial · Observational
A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this observational study is to evaluate the safety and efficacy of Adebrelimab Injection in extensive-stage small cell lung cancer (ES-SCLC) under real-world conditions. Specifically, the study aims to assess the treatment of Adebrelimab Injection across various subgroups of ES-SCLC patients. The goal is to provide information on treatment patterns and effectiveness in real-life settings, explore potential predictive or prognostic biomarkers, and preliminarily evaluate the pharmacoeconomic indicators of Adebrelimab Injection treatment for extensive-stage small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Lung Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| First-line Adebrelimab regiment for advanced stage ES-SCLC | Drug | — | UNRESOLVED |
| Second-line and beyond Adebrelimab regiment for advanced stage ES-SCLC | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- First-line treatment for advanced stage
- description
- Any first-line regiment including Adebrelimab for advanced stage ES-SCLC
- interventionNames
- Drug: First-line Adebrelimab regiment for advanced stage ES-SCLC
- label
- Second-line and beyond for advanced stage
- description
- Any Second- or later-line and regiment including Adebrelimab for advanced stage ES-SCLC
- interventionNames
- Drug: Second-line and beyond Adebrelimab regiment for advanced stage ES-SCLC
Primary outcomes (1)
- measure
- Safety (The occurrence of ≥3 grade AEs)
- timeFrame
- From August 2024, patients will be followed up for 90 days after the last use of Adebrelimab
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must meet all of the following criteria to be eligible for inclusion in this study: 1. Voluntarily sign the informed consent form and agree to participate in the study. 2. Histopathologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC). 3. Age ≥ 18 years. 4. Determined by the investigator to be eligible for Adebrelimab treatment. Exclusion Criteria: * Patients with any of the following conditions are not eligible for inclusion in this study: 1. Evidence of being a pregnant or lactating female. 2. Currently receiving treatment as part of a blinded study protocol. 3. Any other condition that the investigator deems unsuitable for inclusion in the study.
References
Publications (2)
- RESULTWang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13. PMID 35576956
- RESULTYin J, Yuan J, Li Y, Fang Y, Wang R, Jiao H, Tang H, Zhang S, Lin S, Su F, Gu J, Jiang T, Lin D, Huang Z, Du C, Wu K, Tan L, Zhou Q. Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial. Nat Med. 2023 Aug;29(8):2068-2078. doi: 10.1038/s41591-023-02469-3. Epub 2023 Jul 24. PMID 37488287